Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2008_594 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine the transcriptional signature of Notch Inhibition by testing hair and blood samples on healthy male volunteers who have received MK0752 vs placebo for possible future biomarkers in the treatment of cancer or Alzheimers Disease
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A | Active Comparator | MK0752 1000 mg |
|
| B | Active Comparator | MK0752 350 mg |
|
| C | Placebo Comparator | Placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MK0752 | Drug | Single dose MK0752 capsules, 1000 mg: there will be a 7-day washout period between treatments. |
|
| Measure | Description | Time Frame |
|---|---|---|
| To evaluate the existing Notch response signature using plucked hair follicle profiling data from health young male volunteers given 1000 mg MK0752 and 350 mg MK0752. | 8.5 hours post dose. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Merck Sharp & Dohme LLC | Study Director |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26765077 | Result | Tanis KQ, Podtelezhnikov AA, Blackman SC, Hing J, Railkar RA, Lunceford J, Klappenbach JA, Wei B, Harman A, Camargo LM, Shah S, Finney EM, Hardwick JS, Loboda A, Watters J, Bergstrom DA, Demuth T, Herman GA, Strack PR, Iannone R. An accessible pharmacodynamic transcriptional biomarker for notch target engagement. Clin Pharmacol Ther. 2016 Apr;99(4):370-80. doi: 10.1002/cpt.335. Epub 2016 Feb 17. |
Not provided
Not provided
| ID | Term |
|---|---|
| C554093 | 3-(4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Comparator: MK0752. | Drug | Single dose MK0752 capsules, 350 mg: there will be a 7-day washout period between treatments. |
|
|
| Comparator: Placebo | Drug | Single dose placebo capsules: there will be a 7-day washout period between treatments. |
|